Acotec Scientific Holdings Limited
Category: AI in Healthcare
Global innovative medical technology enterprise focusing on R&D and application of technology platforms in vascular interventional treatment Acotec Scientific Holdings Limited was founded in 2011. The company is led by Jing Li. Based in Beijing, China. Team size: 500+. Total funding raised: $523M. Latest round: Majority stake acquisition by Boston Scientific (completed February 2023). Key investors include Boston Scientific (majority stakeholder).
- Founded
- 2011
- Headquarters
- Beijing, China
- Team size
- 500+
- Total funding
- $523M
Value proposition
Provide innovative and high-quality medical solutions for vascular diseases with focus on drug-coated balloons and interventional devices
Products and solutions
Drug-Coated Balloons (DCB), Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters, Thrombus Aspiration Catheters, Radiofrequency Ablation Technologies, Electro Physiologic (EP) Catheters, Coronary Artery Balloon Dilatation Catheters, Microcatheters (V-Otter), Peripheral Vascular Aspiration Systems
Unique value
Pioneer in Chinese market for drug-coated balloons (DCB); first to launch peripheral DCB in China with breakthrough FDA designation for below-the-knee DCB
Target customer
Hospitals, clinics, and healthcare providers specializing in vascular and cardiac interventional procedures
Industries served
Healthcare, Medical Devices, Vascular Intervention, Cardiology
Technology advantage
Strong R&D capabilities in vascular interventional treatment with four technology platforms: drug-coating, RF ablation, polymer material, and aspiration technologies
How they differentiate
Specializes in drug-coated balloons and innovative vascular interventional devices with strong R&D focus and first-mover advantage in Chinese DCB market
Main competitors
Terumo, Medtronic, Abbott
Key partnerships
Boston Scientific (majority shareholder since 2023), Extended collaboration agreement through December 2028
Major milestones
Boston Scientific acquired majority stake in February 2023, FDA Breakthrough Device Designation for below-the-knee DCB (2019), HKEX listing in 2021, Extended strategic collaboration with Boston Scientific through 2028
Growth metrics
2024: Revenue increased 12.7% and profit rose 264%; 2025 Interim: Revenue increased 20.1% and profit increased 124.1%
Market positioning
Significant player in Chinese vascular interventional device market; strengthened global position as part of Boston Scientific group
Geographic focus
Primary focus on China with expansion into global markets, notably Asia-Pacific and international markets through Boston Scientific partnership
Patents and IP
Proprietary drug-coated balloon technology; specific patent details not publicly disclosed
About Jing Li
Chairman of the Board and Executive Director at Acotec Scientific Holdings Limited since 2017. Founder of the company with over 8 years of leadership experience in medical device innovation and vascular interventional treatment.
Official website: https://eninvestor.acotec.com